Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Preparation and characterization of conjugates of recombinant CD4 and deglycosylated ricin A chain using different cross-linkers.

Bioconjug Chem. 1990 Jan-Feb;1(1):24-31. Unique Identifier : AIDSLINE MED/91248847
Ghetie V; Till MA; Ghetie MA; Tucker T; Porter J; Patzer EJ; Richardson JA; Uhr JW; Vitetta ES; Department of Microbiology, University of Texas Southwestern; Medical Center, Dallas 75235.

Abstract: In a previous study, we have demonstrated that conjugates containing soluble, recombinant human CD4 (rCD4) and the deglycosylated form of ricin A chain (dgA) (rCD4-dgA) effectively kill a human T cell line infected with the human immunodeficiency virus (HIV) in vitro. In contrast, such conjugates are 100-1000-fold less toxic to uninfected cells. In order to use a rCD4-dgA conjugate effectively in vivo, it was important to demonstrate that (1) it binds to and kills HIV-infected, but not uninfected, human cells, (2) it is stable in the circulation, and (3) it has an optimal therapeutic index (toxicity to animals versus toxicity to target cells). A major factor affecting the efficacy of such conjugates in vitro and in vivo is the nature of the cross-linker between the ligand (rCD4) and the toxin (dgA). In this report, we have prepared rCD4-dgA conjugates using three different cross-linkers. Different methods of purification have been compared by determining the optimal yield, purity, and retention of biological activity (i.e., binding to gp120 and dgA chain activity). The structure of these conjugates as well as their cytotoxicity to target cells in vitro has been analyzed. Finally, we have compared their pharmacokinetics, tissue localization, and toxicity in mice.

Keywords: Animal *Antigens, CD4/*CHEMICAL SYNTHESIS/ISOLATION & PURIF/METABOLISM/ TOXICITY Binding, Competitive Cell Line Cell Survival/DRUG EFFECTS Chromatography, Affinity Chromatography, Gel Chromatography, High Pressure Liquid Chromatography, Ion Exchange Cross-Linking Reagents Glycosylation Human HIV/DRUG EFFECTS HIV Envelope Protein gp120/METABOLISM Indicators and Reagents Mice Molecular Weight Recombinant Proteins/*CHEMICAL SYNTHESIS/ISOLATION & PURIF/ METABOLISM/TOXICITY *Ricin/*CHEMICAL SYNTHESIS/ISOLATION & PURIF/METABOLISM/TOXICITY Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
910930
M9190682

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .